Opinion|Videos|August 9, 2024
Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024
Key opinion leaders (KOLs) examine real-world evidence and draw on their clinical experiences to inform their practice, discussing real-world dose escalations and key insights gained from practical application.
Advertisement
Episodes in this series
- Focusing on real-world evidence (RWE), how do outcomes compare what’s seen in practice and how does that impact your choice of therapy?
- Real-world dose escalation and outcomes of luspatercept across all LOTs (
Patel K, et al. EHA 2024. Abstract P768. ) - IMerge study, PROs in heavily pre-treated patients with LR-MDS:
Sekeres MA, et al. Blood. 2023; 142 (suppl 1):6479. - Real World Data Replicates Medalist Study Results (
Komrokji RS et al. Blood 2022 )
- Real-world dose escalation and outcomes of luspatercept across all LOTs (
- Can each of you share any key takeaways or additional data updates surrounding lower-risk MDS presented at EHA 2024? (if time permits)
- Let’s discuss novel agents and/or combination strategies in LR-MDS through ongoing research that may shape the future treatment landscape.
- Luspatercept plus erythropoietin in LR-MDS:
Jonasova A, et al. EHA 2024. Abstract P1886 . - Luspatercept plus ESA combinations in LR-MDS:
Komrokji RS, et al. Blood Adv. 2023. - Ph 2 study, elritercept (KER-050):
Díez Campelo M, et al. EHA 2024. Abstract S183 .
- Luspatercept plus erythropoietin in LR-MDS:
Advertisement
Related to this article
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
Japan approved subcutaneous pembrolizumab and berahyaluronidase alfa across all indications for which intravenous pembrolizumab is approved in the country.
New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5